biostudies-literatureAntonarakis ESNCI NIH HHS4662-4671https://www.ebi.ac.uk/biostudies/studies/S-EPMC6481607biostudies-literatureUnknown24(19)<b>Purpose:</b> Sipuleucel-T is FDA approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) based on the IMPACT trial showing a 4.1-month benefit in median overall survival (OS) for patients receiving sipuleucel-T versus control. Although efficacy of sipuleucel-T is well established, its mechanism remains incompletely understood.<b>Patients and Methods:</b> Patient samples from three sipuleucel-T trials were assessed for peripheral cellular immune responses to the immunogen PA2024 and the target antigen prostatic acid phosphatase (PAP). PAP- and PA2024-specific proliferative and cytolytic responses were characterized to delineate sipuleucel-T-induced immune responses. To quantify potential cytotoxic T lymphocyte (CTL) activity, cell-surface CD107a expression oClinical cancer research : an official journal of the American Association for Cancer ResearchAntigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.PMC6481607P30 CA006973Petrylak DPQuinn DIKibel ASCampogan DDearstyne ESmall EJHarmon MHaynes HChang NNAntonarakis ESDrake CGVu TSheikh NAfalseAntigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.<b>Purpose:</b> Sipuleucel-T is FDA approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) based on the IMPACT trial showing a 4.1-month benefit in median overall survival (OS) for patients receiving sipuleucel-T versus control. Although efficacy of sipuleucel-T is well established, its mechanism remains incompletely understood.<b>Patients and Methods:</b> Patient samples from three sipuleucel-T trials were assessed for peripheral cellular immune responses to the immunogen PA2024 and the target antigen prostatic acid phosphatase (PAP). PAP- and PA2024-specific proliferative and cytolytic responses were characterized to delineate sipuleucel-T-induced immune responses. To quantify potential cytotoxic T lymphocyte (CTL) activity, cell-surface CD107a expression o2018-01-01T00:00:00Z2018 Oct2026-05-03T19:31:38.798Z2019-06-06T22:48:46ZS-EPMC64816072985821810.1158/1078-0432.ccr-18-063810.1158/1078-0432.CCR-18-0638